Marker Therapeutics (MRKR) Shares Outstanding (Diluted Average) (2011 - 2026)

Marker Therapeutics (MRKR) has 13 years of Shares Outstanding (Diluted Average) data on file, last reported at $19.3 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $19.3 million, up 73.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.3 million (up 73.91% YoY), and the FY2025 annual result was $15.3 million, up 70.49% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $19.3 million in Q1 2026 per MRKR's latest filing, from $15.3 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $19.3 million in Q1 2026 and troughed at $8.3 million in Q1 2022.
• A 5-year average of $10.6 million and a median of $8.9 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) slumped 88.75% in 2022, then soared 87.98% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $8.4 million in 2022, then climbed by 5.49% to $8.8 million in 2023, then increased by 1.94% to $9.0 million in 2024, then jumped by 70.49% to $15.3 million in 2025, then advanced by 26.16% to $19.3 million in 2026.
• Business Quant data shows MRKR's Shares Outstanding (Diluted Average) at $19.3 million in Q1 2026, $15.3 million in Q4 2025, and $16.8 million in Q3 2025.